We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
SUBSCRIBE: eNewsletter
Are you a US-based MD who sees patients with neurologic disorders and who likes to write? Why not blog for NeurologyTimes.com? It's your place to be heard on topics that keep you up at night. Contact us here and we can send you the details.
© Stokkete/Shutterstock.com
From no evidence of disease activity in MS to studies of a new treatment for periodic paralysis, AAN 2016 featured many exciting clinical trials.
Interactive case study discussions highlighted the issue that treating multiple sclerosis often involves swimming murky waters.
Three new studies on multiple sclerosis discuss potential ways to prevent the development of cognitive problems, or the development of the disease.
By studying first-degree relatives of patients with MS, can researchers perfect a risk algorithm for the disease?
Researchers investigated a possible quantitative measure of taste function that correlated with myelin-related lesions found in MS patients.
Risk factors regarding MS, including genetic research findings and progressive multifocal leukoencephalopathy while taking natalizumab, are discussed.
Our Feb. news & research include two new migraine drugs, the stroke-Parkinson link, and the potential of an anticancer drug to prevent Alzheimer.
Neuropsychological deficits often remain undiscovered during routine clinical examinations of multiple sclerosis patients due to time constraints.
Our Jan. news & research list includes the possible lingering effects of childhood concussion and the benefits of vitamin D for MS.
New findings regarding viruses and neuronal cells could provide clues for possible new therapies for MS and Alzheimer disease.
